Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: Implication for gene therapy with adenovirus vectors

Pediatrics

Volumn 101, Issue 6, 1998, Pages 1013-1019

  Piedra, Pedro A ^a   Poveda, Gustavo A ^a   Ramsey, Bonnie ^b   McCoy, Karen ^c   Hiatt, Peter W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Adenovirus; CF children; Neutralizing antibodies to adenoviruses

Indexed keywords

NEUTRALIZING ANTIBODY; TRANSMEMBRANE CONDUCTANCE REGULATOR; VIRUS ANTIBODY; VIRUS VECTOR;

ADENOVIRUS; ADULT; ANTIBODY RESPONSE; ARTICLE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; GENE THERAPY; HUMAN; INCIDENCE; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS TYPING;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ADULT; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INCIDENCE; INFANT; MALE; NEUTRALIZATION TESTS; PREVALENCE;

EID: 0031864774     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.101.6.1013     Document Type: Article

References (28)

1. Petersen NT, Hoiby N, Mordhorst CH, Lind K, Flensborg EW, Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasma - possible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand. 1981;70:623-628
2. Wang EEL, Prober CG, Manson B, Corey M, Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med. 1984;311:1653-1658
3. Riordan JR, Rommens JM, Kerem BS, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066-1073
4. Anderson MP, Rich DP, Gregory RJ, Smith AE, Welsh MJ. Generation of cAMP-activated chloride currents by expression of CFTR. Science. 1991; 251:679-682
5. Rosenfeld MA, Yoshimura K, Trapnell BC, et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell. 1992;68:143-155
6. Barranger JA, Bahnson AB, Nimgaonkar MT, et al. Gene therapy for genetic disease. Int Pediatr. 1995;10:5-9
7. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nature Genetics. 1992;2:21-25
8. Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques. 1988;6:616-629
9. Yang Y, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995;69:2004-2015
10. Yang Y, Su Q, Grewal IS, Schilz R, Flavell RA, Wilson JM. Transient subversion of CD40 Iigand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol. 1996;70: 6370-6377
11. Yang Y, Nunes FA, Berencsi K, Furth EE, Gönczöl E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA. 1994;91:4407-4411
12. Engelhardt JF, Simon RH, Yang Y, et al. Adenovirus-mediated transfer of the CFTR gene to the lung of nonhuman primates: biological efficacy study. Hum Gene Ther. 1993;4:759-769
13. Zabner J, Petersen DM, Puga AP, et al. Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR CDNA to airway epithelia of primates and cotton rats. Nature Genetics. 1994;6:75-83
14. Wadell G. Molecular epidemiology of human adenoviruses. Curr Top Microbiol Immunol. 1984;110:191-220
15. Hierholzer JC, Wigand R, Anderson LJ, Anderson LJ, Adrian T, Gold JWM. Adenoviruses from patients with AIDS: a plethora of serotypes and a description of five new serotypes of subgenus D (types 43-47). J Infect Dis. 1988;158:804-813
16. Fox JP, Brandt CD, Wassermann FE, et al. The Virus Watch program: a continuing surveillance of viral infections in metropolitan New York families. VI. Observation of adenovirus infection: virus excretion patterns, antibody response, efficacy of surveillance, patterns of infection and relation to illness. Am J Epidemiol. 1969;89:25-50
17. Brandt CD, Kim HW, Vargosko AJ, et al. Infections in 18 000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologie type and illness syndrome. Am J Epidemiol. 1969;90:484-499
18. Schmitz H, Wigand R, Heinrich W. Worldwide epidemiology of human adenovirus infections. Am J Epidemiol. 1983;117:455-466
19. Braithwaite AW, Bellett AJD, Müllbacher A, Zhang X. Human adenoviruses: genetics and immunobiology. In: Thomas DB, ed. Viruses and the Cellular Immune Responses. New York, NY: Marcel Dekker, Inc; 1993
20. Piedra PA. Enteroviruses/Adenoviruses. In: Patrick CC, ed. Infections in Immunocompromised Infants and Children. New York, NY: Churchill Livingstone, Inc; 1992:662-668
21. Edmondson WP, Purcell RH, Gundelfinger BF, Love JWP, Ludwig W, Chanock RM. Immunization by selective infection with type 4 adenovirus grown in human diploid tissue culture, II Specific protective effect against epidemic disease. JAMA. 1996;195:453-459
22. Piedra PA, Grace S, Jewell A, et al. Purified fusion protein (PFP-2) vaccine protects against lower respiratory tract illness during respiratory syncytial virus (RSV) season in children with cystic fibrosis. Pediatr Infect Dis J. 1996;15:23-31
23. Piedra PA, Kasel JA, Norton HJ, et al. Description of an adenovirus type 8 outbreak in hospitalized neonates born prematurely. Pediatr Infect Dis J. 1992;11:460-465
24. Payne SB, Grilli EA, Smith AJ. Investigation of an outbreak of adenovirus type 3 infection in a boys' boarding school. J Hyg Cambridge. 1984;93:277-283
25. Selivanov AA, Pleshanova RA, Skryabina EA, Smorodintsev AA. Testing the effectiveness of live adenovirus vaccine. I. Reactogenic properties. Acta Virol 1964;8:263-270
26. Selivanov AA, Pleshanova RA, Smorodintsev AA. Testing the effectiveness of live adenovirus vaccine. I. Immunogenic properties. Acta Virol. 1964;8:271-276
27. Kasel JA, Banks PA, Wigand R, Knight V, Alling DW. An immunologic classification of heterotypic antibody responses to adenoviruses in man. Soc Exp Biol Med. 1965;119:1162-1165
28. Rosenecker J, Harms K-H, Bertele RM, Pohl-Koppe A, Mutius E, Nicolai AT. Adenovirus infection in cystic fibrosis patients: implication for the use of adenoviral vectors for gene transfer. Infection. 1996;24:5-8